SEC Form 4 · accession 0001723128-19-000038
Amneal Pharmaceuticals, Inc. · AMRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter R Terreri
Director
Period of report
Mar 6, 2019
Accepted (ET)
Mar 7, 2019 · 5:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001723128
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF1 | Mar 6, 2019 | S | 23,345 | $12.39 | D | 25,192 | D | |
| Class A Common Stock | Mar 6, 2019 | M | 45,000 | $6.55 | A | 70,192 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF2 | $6.55 | Mar 6, 2019 | M | 45,000 | D | — | May 20, 2019 | Class A Common Stock | 45,000 | 0 | D |
Explanation of responses
- F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.39 per share to $12.38 per share. The reporting person undertakes to provide Amneal Pharmaceuticals, Inc., any security holder of Amneal Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2The option is vested and currently exercisable.
Remarks
Exhibit 24 - Power of Attorney